Psychedelic Drugs Market: By Drugs (Lysergic Acid Diethylamide (LSD), 3,4-MethylEnedioxyMethamphetamine (Ecstasy), Phencyclidine, Gamma Hydroxybutyric Acid (GHB), Etamine, Ayahuasca, Salvia, Psilocybin, Others), By Application (Resistant depression, panic disorder, post-traumatic stress disorder, Opiate Addiction, Others), By End User (Hospitals, Homecare, Specialty Clinics, Others) and Geography

Purchase Option

$ 4400
$ 6600
$ 8900

Psychedelic Drugs Market size was valued at USD 543.9 million in 2022 and is poised to grow at a significant CAGR of 38.5% from  2023-2029. Psychedelic drugs enhance or change sensory perceptions, energy levels, cognitive processes, and spiritual experiences. Psychedelic drugs are classified into dissociative medications (such as phencyclidine), empathogens, and serotonergic drugs (such as lysergic acid diethylamide). These drugs treat many conditions, including major depression, treatment-resistant depression, panic disorder, post-traumatic stress disorder, and opiate addiction. Based on the end user, the psychedelic drug market is segmented into Hospitals, Homecare, Specialty Clinics, and Others. The hospital/pharmacy segment is anticipated to grow at a significant CAGR over the forecast years, During the COVID-19 pandemic, demand for psychedelic drugs increased as hospital pharmacies were overburdened with treating patients' mental health disorders, boosting segment growth even further. The growing global awareness of people's mental health and the use of psychedelic drugs for specific indications is driving the growth of hospital pharmacies as a distribution channel. The anti-inflammatory activity of psychedelic drugs has also contributed to the market's growth. Growing acceptance of psychedelic drugs for treating depression, increasing prevalence of depression and mental disorders, rising awareness of mental health, and growing r&d activities in psychedelic drugs are a few factors driving the industry's growth over the forecasting period.

Psychedelic Drugs Market Key Developments:
  • In August 2020, Janssen Pharmaceuticals, Inc.'s Spravato nasal spray was approved to treat suicidal patients. According to published data, approximately 11-12% of Americans suffer from major depressive disorder, which leads to suicide. As a result, this approval provided these patients with exceptional therapy while also allowing the company to generate more revenue.

Psychedelic Drugs Market Summary

Study Period

2024-2030

Base Year

2023

CAGR

38.5%

Largest Market

North America

Fastest Growing Market

Asia Pacific
Psychedelic Drugs Market Dynamics

Psychedelics have grown in popularity in the last decade because they are used in human mental healing and treatment practices and can heal the mind. Researchers and scientists are investigating the therapeutic value of psychedelic drugs and compounds that could be a new treatment option for people suffering from depression. Continuous research and development in psychedelic drugs have increased the medication's acceptance. Psychedelic drugs' promising outcomes have increased their use in the United States and other regions, resulting in rising demand for psychedelic drugs; thus, these factors are expected to act as market drivers.

Key Features of the Reports

  • The psychedelic drugs market report provides granular level information about the market size, regional market share, historic market (2018 to 2022) and forecast (2023 to 2029)
  • The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
  • The report tracks recent innovations, key developments and startup’s details that are actively working in the market
  • The report provides plethora of information about market entry strategies, regulatory framework and reimbursement scenario
  • The report analyses the impact of socio-political environment through PESTLE Analysis and competition through Porter’s Five Force Analysis in addition to recent technology advancements and innovations in the market

Psychedelic Drugs Market Segmentation

By Drugs
  • Lysergic Acid Diethylamide (LSD)
  • 3,4-MethylEnedioxyMethamphetamine (Ecstasy)
  • Phencyclidine
  • Gamma Hydroxybutyric Acid (GHB)
  • Etamine
  • Ayahuasca
  • Salvia
  • Psilocybin
  • Others
By Application
  • Resistant depression
  • Panic disorder
  • Post-traumatic stress disorder
  • Opiate Addiction
  • Others
By End User
  • Hospitals
  • Homecare
  • Specialty Clinics
  • Others
By Geography
  • North America
  • Europe
  • The Asia Pacific
  • Latin America
  • MEA
LOCATION

Geography

Frequently Asked Questions

The Psychedelic Drugs Market size was valued at USD 543.9 million in 2022

The Psychedelic Drugs Market's key players are: Roche Holding AG Pfizer Inc. The Emmes Company COMPASS Group plc Merck & Co. Inc. AstraZeneca PLC AbbVie Inc. Mylan N.V. Alkermes plc Dr. Reddy’s Laboratories

The Psychedelic Drugs Market has been classified into North America, Asia Pacific, Europe, Latin America, Middle East and Africa, and the rest of MEA.

1. Executive Summary
2. Global Psychedelic Drugs Market Introduction 
2.1.Global Psychedelic Drugs Market  - Taxonomy
2.2.Global Psychedelic Drugs Market  - Definitions
2.2.1.Drugs 
2.2.2.Application 
2.2.3.End User 
2.2.4.Geography
2.2.5.Region
3. Global Psychedelic Drugs Market Dynamics
3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Trends
3.5. Product Landscape
3.6. New Product Launches
3.7. Impact of COVID 19 on Market
4.Global Psychedelic Drugs Market Analysis, 2018 - 2022 and Forecast 2023 - 2029
4.1.  Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
4.2.  Year-Over-Year (Y-o-Y) Growth Analysis (%) 
4.3.  Market Opportunity Analysis 
5.Global Psychedelic Drugs Market  By Drugs , 2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million)
5.1. Lysergic Acid Diethylamide (LSD)
5.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
5.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.1.3. Market Opportunity Analysis 
5.2. 3,4-MethylEnedioxyMethamphetamine (Ecstasy)
5.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
5.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.2.3. Market Opportunity Analysis 
5.3. Phencyclidine
5.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
5.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.3.3. Market Opportunity Analysis 
5.4. Gamma Hydroxybutyric Acid (GHB)
5.4.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
5.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.4.3. Market Opportunity Analysis 
5.5. Etamine
5.5.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
5.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.5.3. Market Opportunity Analysis 
5.6. Ayahuasca
5.6.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
5.6.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.6.3. Market Opportunity Analysis 
5.7. Salvia
5.7.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
5.7.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.7.3. Market Opportunity Analysis 
5.8. Psilocybin
5.8.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
5.8.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.8.3. Market Opportunity Analysis 
5.9. Others
5.9.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
5.9.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.9.3. Market Opportunity Analysis 
6. Global Psychedelic Drugs Market  By Application , 2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million)
6.1. Resistant depression
6.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
6.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.1.3. Market Opportunity Analysis 
6.2. Panic disorder
6.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
6.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.2.3. Market Opportunity Analysis 
6.3. Post-traumatic stress disorder
6.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
6.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.3.3. Market Opportunity Analysis 
6.4. Opiate Addiction
6.4.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
6.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.4.3. Market Opportunity Analysis 
6.5. Others
6.5.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
6.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.5.3. Market Opportunity Analysis 
7. Global Psychedelic Drugs Market  By End User , 2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million)
7.1. Hospitals
7.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
7.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
7.1.3. Market Opportunity Analysis 
7.2. Homecare
7.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
7.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
7.2.3. Market Opportunity Analysis 
7.3. Specialty Clinics
7.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
7.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
7.3.3. Market Opportunity Analysis 
7.4. Others
7.4.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
7.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
7.4.3. Market Opportunity Analysis 
8. Global Psychedelic Drugs Market  By Geography, 2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million)
8.1. North America
8.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
8.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.1.3. Market Opportunity Analysis 
8.2. Europe
8.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
8.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.2.3. Market Opportunity Analysis 
8.3. The Asia Pacific
8.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
8.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.3.3. Market Opportunity Analysis 
8.4. Latin America
8.4.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
8.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.4.3. Market Opportunity Analysis 
8.5. MEA
8.5.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
8.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.5.3. Market Opportunity Analysis 
9. Global Psychedelic Drugs Market  By Region, 2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million)
9.1. North America
9.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
9.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
9.1.3. Market Opportunity Analysis 
9.2. Europe
9.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
9.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
9.2.3. Market Opportunity Analysis 
9.3. Asia Pacific (APAC)
9.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
9.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
9.3.3. Market Opportunity Analysis 
9.4. Middle East and Africa (MEA)
9.4.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
9.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
9.4.3. Market Opportunity Analysis 
9.5. Latin America
9.5.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
9.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
9.5.3. Market Opportunity Analysis 
10. North America Psychedelic Drugs Market ,2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million)
10.1. Drugs  Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.1.1.Lysergic Acid Diethylamide (LSD)
10.1.2.3,4-MethylEnedioxyMethamphetamine (Ecstasy)
10.1.3.Phencyclidine
10.1.4.Gamma Hydroxybutyric Acid (GHB)
10.1.5.Etamine
10.1.6.Ayahuasca
10.1.7.Salvia
10.1.8.Psilocybin
10.1.9.Others
10.2.  Application  Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.2.1.Resistant depression
10.2.2.Panic disorder
10.2.3.Post-traumatic stress disorder
10.2.4.Opiate Addiction
10.2.5.Others
10.3.  End User  Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.3.1.Hospitals
10.3.2.Homecare
10.3.3.Specialty Clinics
10.3.4.Others
10.4.  Geography Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.4.1.North America
10.4.2.Europe
10.4.3.The Asia Pacific
10.4.4.Latin America
10.4.5.MEA
10.5.  Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.5.1.United States of America (USA)
10.5.2.Canada
11. Europe Psychedelic Drugs Market ,2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million)
11.1. Drugs  Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.1.1.Lysergic Acid Diethylamide (LSD)
11.1.2.3,4-MethylEnedioxyMethamphetamine (Ecstasy)
11.1.3.Phencyclidine
11.1.4.Gamma Hydroxybutyric Acid (GHB)
11.1.5.Etamine
11.1.6.Ayahuasca
11.1.7.Salvia
11.1.8.Psilocybin
11.1.9.Others
11.2.  Application  Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.2.1.Resistant depression
11.2.2.Panic disorder
11.2.3.Post-traumatic stress disorder
11.2.4.Opiate Addiction
11.2.5.Others
11.3.  End User  Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.3.1.Hospitals
11.3.2.Homecare
11.3.3.Specialty Clinics
11.3.4.Others
11.4.  Geography Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.4.1.North America
11.4.2.Europe
11.4.3.The Asia Pacific
11.4.4.Latin America
11.4.5.MEA
11.5.  Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.5.1.Germany
11.5.2.France
11.5.3.Italy
11.5.4.United Kingdom (UK)
11.5.5.Spain
11.5.6.Rest of EU
12. Asia Pacific (APAC) Psychedelic Drugs Market ,2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million)
12.1. Drugs  Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.1.1.Lysergic Acid Diethylamide (LSD)
12.1.2.3,4-MethylEnedioxyMethamphetamine (Ecstasy)
12.1.3.Phencyclidine
12.1.4.Gamma Hydroxybutyric Acid (GHB)
12.1.5.Etamine
12.1.6.Ayahuasca
12.1.7.Salvia
12.1.8.Psilocybin
12.1.9.Others
12.2.  Application  Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.2.1.Resistant depression
12.2.2.Panic disorder
12.2.3.Post-traumatic stress disorder
12.2.4.Opiate Addiction
12.2.5.Others
12.3.  End User  Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.3.1.Hospitals
12.3.2.Homecare
12.3.3.Specialty Clinics
12.3.4.Others
12.4.  Geography Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.4.1.North America
12.4.2.Europe
12.4.3.The Asia Pacific
12.4.4.Latin America
12.4.5.MEA
12.5.  Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.5.1.China
12.5.2.India
12.5.3.Australia and New Zealand (ANZ)
12.5.4.Japan
12.5.5.Rest of APAC
13. Middle East and Africa (MEA) Psychedelic Drugs Market ,2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million)
13.1. Drugs  Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.1.1.Lysergic Acid Diethylamide (LSD)
13.1.2.3,4-MethylEnedioxyMethamphetamine (Ecstasy)
13.1.3.Phencyclidine
13.1.4.Gamma Hydroxybutyric Acid (GHB)
13.1.5.Etamine
13.1.6.Ayahuasca
13.1.7.Salvia
13.1.8.Psilocybin
13.1.9.Others
13.2.  Application  Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.2.1.Resistant depression
13.2.2.Panic disorder
13.2.3.Post-traumatic stress disorder
13.2.4.Opiate Addiction
13.2.5.Others
13.3.  End User  Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.3.1.Hospitals
13.3.2.Homecare
13.3.3.Specialty Clinics
13.3.4.Others
13.4.  Geography Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.4.1.North America
13.4.2.Europe
13.4.3.The Asia Pacific
13.4.4.Latin America
13.4.5.MEA
13.5.  Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.5.1.GCC Countries
13.5.2.South Africa
13.5.3.Rest of MEA
14. Latin America Psychedelic Drugs Market ,2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million)
14.1. Drugs  Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
14.1.1.Lysergic Acid Diethylamide (LSD)
14.1.2.3,4-MethylEnedioxyMethamphetamine (Ecstasy)
14.1.3.Phencyclidine
14.1.4.Gamma Hydroxybutyric Acid (GHB)
14.1.5.Etamine
14.1.6.Ayahuasca
14.1.7.Salvia
14.1.8.Psilocybin
14.1.9.Others
14.2.  Application  Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
14.2.1.Resistant depression
14.2.2.Panic disorder
14.2.3.Post-traumatic stress disorder
14.2.4.Opiate Addiction
14.2.5.Others
14.3.  End User  Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
14.3.1.Hospitals
14.3.2.Homecare
14.3.3.Specialty Clinics
14.3.4.Others
14.4.  Geography Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
14.4.1.North America
14.4.2.Europe
14.4.3.The Asia Pacific
14.4.4.Latin America
14.4.5.MEA
14.5.  Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
14.5.1.Brazil
14.5.2.Mexico
14.5.3.Rest of LA
15. Competition Landscape
15.1.  Market Player Profiles (Introduction, Brand/Product Sales, Financial Analysis, Product Offerings, Key Developments, Collaborations, M & A, Strategies, and SWOT Analysis) 
15.2.1.Roche Holding AG
15.2.2.Pfizer Inc.
15.2.3.The Emmes Company 
15.2.4.COMPASS Group plc 
15.2.5.Merck & Co. Inc.
15.2.6.AstraZeneca PLC 
15.2.7.AbbVie Inc.
15.2.8.Mylan N.V.
15.2.9.Alkermes plc 
15.2.10.Dr. Reddy’s Laboratories
16. Research Methodology 
17. Appendix and Abbreviations 
  • Roche Holding AG
  • Pfizer Inc.
  • The Emmes Company 
  • COMPASS Group plc 
  • Merck & Co. Inc.
  • AstraZeneca PLC 
  • AbbVie Inc.
  • Mylan N.V.
  • Alkermes plc 
  • Dr. Reddy’s Laboratories

Adjacent Markets